| Isis Pharmaceuticals News (2003-2004) |
 |
| Tuesday, August 19, 2008 |
| Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors Posted 7:26 AM PST |
| |
| Wednesday, August 13, 2008 |
| Isis Initiates Clinical Trial of CRP Drug; Reduction of CRP with ISIS 353512 could provide therapeutic benefit in cardiovascular, renal and inflammatory diseases Posted 8:05 AM PST |
| |
| Wednesday, August 6, 2008 |
| Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen Posted 4:38 PM PST |
| |
| Monday, August 4, 2008 |
| CARLSBAD--- Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance Posted 5:53 AM PST |
| |
| Thursday, July 17, 2008 |
| CARLSBAD--- Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer Posted 7:23 AM PST |
| |
| Tuesday, July 1, 2008 |
| CARLSBAD--- Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences Posted 7:45 AM PST |
| |
| Tuesday, June 24, 2008 |
| Genzyme and Isis Complete Licensing of Mipomersen Posted 9:19 AM PST |
| |
| Tuesday, June 10, 2008 |
| Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference Posted 6:11 PM PST |
| |
| Monday, June 2, 2008 |
| Isis' Partners Present Clinical Data on Antisense Drugs at the American Society of Clinical Oncology Posted 3:19 PM PST |
| |
| Tuesday, May 27, 2008 |
| CARLSBAD--- Isis to Receive $4.6 Million From Alnylam Posted 8:18 AM PST |
| |
| Wednesday, May 21, 2008 |
| Isis Files S-3 Registration Statement Posted 2:48 PM PST |
| |
| Friday, April 25, 2008 |
| FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen Posted 6:36 AM PST |
| |
| Friday, April 18, 2008 |
| Isis Reports Reduction of apoB-100 Levels in a Murine Model Resulting in Up to 92% Reduction of Atherosclerosis Posted 6:13 AM PST |
| |
| Thursday, April 17, 2008 |
| Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance Posted 7:37 AM PST |
| |
| Tuesday, April 8, 2008 |
| Briston-Myers Squibb Selects ISIS Drug Targeting PCSK9 for Prevention and Treatment of Cardiovascular Disease Posted 8:32 AM PST |
| |
| Tuesday, February 12, 2008 |
| Isis Announces Approximately $2.8 Million in Government Grants and Contracts Awarded to its Ibis Subsidiary to Advance Ibis' Pathogen Identification Technology Posted 8:08 AM PST |
| |
| Friday, February 1, 2008 |
| Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration Posted 8:27 AM PST |
| |
| Thursday, January 31, 2008 |
| CARLSBAD--- Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity Posted 8:37 AM PST |
| |
| Monday, January 7, 2008 |
| Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen Posted 3:28 PM PST |
| |
| Tuesday, December 18, 2007 |
| SAN DIEGO--- Forward Ventures Joins Series A Syndicate for Newly Formed Altair Therapeutics Posted 5:41 AM PST |
| |
| Monday, December 17, 2007 |
| CARLSBAD--- Sis Announces Appointment of B. Lynne Parshall as Chief Operating Officer Posted 7:39 AM PST |
| |
| Wednesday, December 12, 2007 |
| Regulus Therapeutics and Collaborators Discover Role of Viral microRNAs in Cancer and Identify First-Ever Example of a Viral microRNA Oncogene Posted 2:43 PM PST |
| |
| Monday, December 3, 2007 |
| CARLSBAD--- Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer Posted 7:39 AM PST |
| |
| Tuesday, November 27, 2007 |
| Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases Posted 8:22 AM PST |
| |
| Thursday, October 18, 2007 |
| Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes Posted 5:49 AM PST |
| |
| Tuesday, October 16, 2007 |
| Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions Posted 4:20 AM PST |
| |
| Tuesday, October 9, 2007 |
| Isis Favorably Revises Financial Guidance and Introduces Mipomersen as Generic Name for ISIS 301012 Posted 4:38 AM PST |
| |
| CARLSBAD--- Isis Receives $1.25 Million Milestone Posted 4:16 AM PST |
| |
| Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012 Posted 4:42 AM PST |
| |
| Friday, October 5, 2007 |
| Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients Posted 5:02 AM PST |
| |
| Wednesday, October 3, 2007 |
| Isis Awarded $1.5 Million NIH Grant to Improve Chemical Properties of RNAi-Based Therapeutics Posted 7:32 AM PST |
| |
| Thursday, September 27, 2007 |
| CARLSBAD--- Isis Acquires Symphony GenIsis Posted 4:47 PM PST |
| |
| Wednesday, September 26, 2007 |
| Isis Announces $1.2 Million Award to Its Ibis Subsidiary to Expand Influenza Detection Capabilities and Enable Large-Scale Influenza Transmission Studies Posted 6:30 AM PST |
| |
| Thursday, September 20, 2007 |
| CARLSBAD, CA--- Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development Posted 8:08 AM PST |
| |
| Thursday, September 13, 2007 |
| Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases Posted 9:37 AM PST |
| |
| Tuesday, September 4, 2007 |
| Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes Posted 10:33 AM PST |
| |
| Tuesday, August 7, 2007 |
| Archemix and Isis Pharmaceuticals Form Strategic Alliance for Aptamer Drug Discovery and Development Posted 4:14 PM PST |
| |
| Monday, July 9, 2007 |
| CARLSBAD--- Isis to Receive $26.5 Million from Alnylam Posted 3:14 PM PST |
| |
| Thursday, May 17, 2007 |
| Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS 301012 in Familial Hypercholesterolemia Patients Posted 8:03 AM PST |
| |
| Thursday, May 10, 2007 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for First Quarter of 2007 Posted 7:54 AM PST |
| |
| Wednesday, May 9, 2007 |
| Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals Posted 7:26 AM PST |
| |
| Thursday, March 8, 2007 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for Fiscal Year 2006 Posted 8:14 AM PST |
| |
| Thursday, March 1, 2007 |
| Alnylam and Isis Announce Allowance of First U.S. Patent Covering Human microRNAs Posted 7:44 AM PST |
| |
| Wednesday, January 24, 2007 |
| Isis Completes Offering of $125 Million Convertible Subordinated Notes to Refinance Existing $125 Million Convertible Subordinated Notes Posted 9:50 AM PST |
| |
| Thursday, January 18, 2007 |
| CARLSBAD--- Isis Pharmaceuticals Enters Into an Agreement to Sell $125.0 Million Convertible Subordinated Notes Due 2027 to Refinance Existing $125.0 Million Convertible Subordinated Notes Due 2009 Posted 10:54 AM PST |
| |
| Tuesday, January 16, 2007 |
| Isis Pharmaceuticals Announces Offering of Convertible Subordinated Notes Posted 4:48 PM PST |
| |
| Thursday, December 21, 2006 |
| Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease Posted 8:00 AM PST |
| |
| Wednesday, December 20, 2006 |
| European Patent Office Upholds Key Isis Patent Protecting Antisense Structures Posted 9:19 AM PST |
| |
| Monday, December 11, 2006 |
| Lilly Highlights Two Collaboration Drugs in Its Pipeline Update Posted 8:23 AM PST |
| |
| Tuesday, December 5, 2006 |
| Isis Receives $1 Million Milestone Payment From Merck on Initiation of Clinical Development of a Compound Discovered in a Collaboration Between the Companies Posted 8:35 AM PST |
| |
| Monday, November 27, 2006 |
| Isis and Alnylam Announce Issued U.S. Patent Broadly Covering Chemical Modifications of Oligonucleotide Therapeutics Posted 5:53 AM PST |
| |
| Monday, November 13, 2006 |
| Isis Pharmaceuticals Reports ISIS 301012 Significantly Reduces All Atherogenic Lipids When Dosed as a Single Agent and When Coadministered With Statins Posted 5:44 AM PST |
| |
| Thursday, November 2, 2006 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter of 2006 Posted 7:07 AM PST |
| |
| Thursday, October 26, 2006 |
| Isis Pharmaceuticals Announces Third Quarter 2006 Financial Results Webcast Posted 7:58 AM PST |
| |
| Tuesday, October 3, 2006 |
| Isis Pharmaceuticals Receives First Commercial Order for Ibis T5000 Biosensor Systems Posted 7:42 AM PST |
| |
| Wednesday, September 20, 2006 |
| Isis Pharmaceuticals Receives Key Patent for Pathogen Identification Methodology Used in Ibis Biosensor System Posted 7:05 AM PST |
| |
| SAN DIEGO--- Kalypsys Appoints 2 Executives to Leadership Team Posted 6:55 AM PST |
| |
| Wednesday, August 23, 2006 |
| SAN DIEGO--- Kemia Closes Series C Financing Posted 2:59 PM PST |
| |
| Wednesday, August 9, 2006 |
| SAN DIEGO--- ADVENTRX Announces Appointment of General Counsel Posted 7:20 AM PST |
| |
| Thursday, August 3, 2006 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for Second Quarter of 2006 Posted 6:52 AM PST |
| |
| Monday, July 31, 2006 |
| Bruker Daltonics and Isis Pharmaceuticals Enter Into Manufacturing and Distribution Agreement for Ibis T5000 Biosensor System Posted 5:01 AM PST |
| |
| Thursday, July 27, 2006 |
| Isis Pharmaceuticals Announces Second Quarter 2006 Financial Results Webcast Posted 9:26 AM PST |
| |
| Tuesday, June 13, 2006 |
| Isis Pharmaceuticals Reports Positive Phase 2 Data: ISIS 113715 Improves Glucose Control in Patients With Type 2 Diabetes Posted 7:13 AM PST |
| |
| Monday, June 12, 2006 |
| Targeting MicroRNAs With Antisense Drugs Produces Compelling Preclinical Data in Animal Studies Posted 10:39 AM PST |
| |
| Multiple Second-Generation Antisense Drugs Show Potential as New Treatments for Metabolic Disorders Posted 3:04 PM PST |
| |
| Thursday, June 1, 2006 |
| Isis Pharmaceuticals Receives Orphan Drug Status for ISIS 301012 for the Treatment of Homozygous Familial Hypercholesterolemia Posted 7:09 AM PST |
| |
| Tuesday, May 30, 2006 |
| CARLSBAD--- Isis Pharmaceuticals Receives $75 Million Equity Financing Commitment Posted 4:28 PM PST |
| |
| Tuesday, May 2, 2006 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for First Quarter of 2006 Posted 3:23 PM PST |
| |
| Thursday, April 27, 2006 |
| Isis Pharmaceuticals Reports Positive Phase 2 Data: ISIS 301012 Reduces Cholesterol and Triglycerides in Patients With High Cholesterol Posted 4:41 PM PST |
| |
| ISIS 301012 Reduces Atherosclerotic Plaques in Animal Models Posted 4:32 PM PST |
| |
| Tuesday, April 18, 2006 |
| Isis Pharmaceuticals Licenses Anti-HIV Drug to ImQuest Pharmaceuticals Posted 4:37 PM PST |
| |
| Friday, April 7, 2006 |
| CARLSBAD--- Isis Pharmaceuticals and Symphony GenIsis Enter Into $75 Million Product Development Collaboration Posted 4:35 PM PST |
| |
| Monday, March 27, 2006 |
| Isis Pharmaceuticals Receives Another Important Antisense Patent Posted 8:08 AM PST |
| |
| Monday, March 13, 2006 |
| ISIS 301012 Does Not Interact With Currently Marketed Lipid Lowering Drugs Posted 7:36 AM PST |
| |
| Thursday, March 9, 2006 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for 2005; Company Meets 2005 Financial Guidance and Previews 2006 Plans Posted 8:39 AM PST |
| |
| Thursday, March 2, 2006 |
| Isis Pharmaceuticals' Financial Results and Highlights for 2005 Conference Call Posted 3:02 PM PST |
| |
| Wednesday, February 22, 2006 |
| Isis Pharmaceuticals and Rosetta Genomics Announce Joint Research Collaboration to Develop Micro-RNA Related Therapies for the Treatment of Liver Cancer Posted 7:36 AM PST |
| |
| Thursday, February 9, 2006 |
| Isis Pharmaceuticals Presents Additional Clinical Data Showing That Isis 301012 Significantly Reduces Triglycerides Posted 7:54 AM PST |
| |
| Isis Pharmaceuticals Reports Clinical Development Goals Posted 3:39 PM PST |
| |
| Tuesday, February 7, 2006 |
| Isis Pharmaceuticals' Oral Formulation of ISIS 301012 Reduces Cholesterol in Humans Posted 8:33 AM PST |
| |
| Monday, February 6, 2006 |
| Isis Pharmaceuticals Initiates Phase 2 Program of ISIS 301012 in Patients With Familial Hypercholesterolemia Posted 7:49 AM PST |
| |
| Tuesday, January 31, 2006 |
| Isis Pharmaceuticals Licenses Proprietary Antibiotic Program to Achaogen Posted 7:54 AM PST |
| |
| Thursday, December 15, 2005 |
| CARLSBAD--- Isis Pharmaceuticals Adds Skip Klein to Board of Directors Posted 8:09 AM PST |
| |
| Wednesday, December 14, 2005 |
| CARLSBAD, CA--- Isis Pharmaceuticals Delivers TIGER Biosensor System to the Department of Homeland Security's National Bioforensic Analysis Center Posted 8:17 AM PST |
| |
| Friday, November 11, 2005 |
| SAN DIEGO--- Xenome Strengthens Management Team and Launches US Presence Posted 4:53 PM PST |
| |
| Tuesday, November 8, 2005 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for the Third Quarter 2005 Posted 9:06 AM PST |
| |
| Monday, November 7, 2005 |
| Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS 301012 in Cardiovascular Disease Posted 9:44 AM PST |
| |
| Tuesday, November 1, 2005 |
| Isis Pharmaceuticals Announces Third Quarter 2005 Financial Results Webcast Posted 9:00 AM PST |
| |
| Tuesday, October 18, 2005 |
| Isis Pharmaceuticals Receives $7 Million From Drug Royalty USA, Inc. Posted 9:14 AM PST |
| |
| Thursday, September 22, 2005 |
| BioMed Realty Trust Acquires San Diego Property From Isis Pharmaceuticals in Sale-Leaseback Transaction; Adds Sixth Property in San Francisco Posted 9:06 AM PST |
| |
| Tuesday, September 20, 2005 |
| Isis Pharmaceuticals Initiates Phase 2 Development of ISIS 301012 for Cardiovascular Disease Posted 4:46 PM PST |
| |
| Tuesday, September 13, 2005 |
| Alnylam and Isis License Intellectual Property for MicroRNA Gene Involved in Hepatitis C Virus Infection; Role of MicroRNA-122 in Hepatitis C Infection Published in Science Posted 8:56 AM PST |
| |
| Monday, September 12, 2005 |
| Isis Pharmaceuticals Expects to Earn Initial Payments of Nearly $4 Million From Alnylam's Recent RNAi Collaboration Posted 7:26 AM PST |
| |
| Tuesday, August 23, 2005 |
| CARLSBAD--- Isis Pharmaceuticals Raises $51 Million in Private Offering Posted 6:23 PM PST |
| |
| CARLSBAD--- Isis Pharmaceuticals Raises $51 Million in Private Offering Posted 6:52 PM PST |
| |
| Monday, August 8, 2005 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for the Second Quarter 2005 Posted 9:51 AM PST |
| |
| Friday, August 5, 2005 |
| Isis Pharmaceuticals Ships First TIGER Biosensor System to the United States Government Posted 10:22 AM PST |
| |
| Thursday, August 4, 2005 |
| ISIS 301012 Continues to Produce Attractive Lipid Reduction Posted 9:50 AM PST |
| |
| Thursday, July 28, 2005 |
| Isis Pharmaceuticals Awarded Contract for Up to $1.1 Million From the United States Government Posted 9:35 AM PST |
| |
| Thursday, July 21, 2005 |
| CARLSBAD, CA--- Isis Pharmaceuticals Awarded Approximately $5 Million From Government Agencies to Advance Additional Application Development for TIGER Biosensor System Posted 10:08 AM PST |
| |
| CARLSBAD--- Isis Pharmaceuticals Awarded Approximately $5 Million From Government Agencies to Advance Additional Application Development for TIGER Biosensor System Posted 10:01 AM PST |
| |
| Monday, July 11, 2005 |
| Isis Pharmaceuticals' TIGER Biosensor System Receives R&D 100 Award Posted 9:18 AM PST |
| |
| Tuesday, June 7, 2005 |
| SAN DIEGO--- CardioDynamics Announces Nomination of B. Lynne Parshall and Robert W. Keith to Board of Directors Posted 9:40 AM PST |
| |
| Thursday, May 26, 2005 |
| Isis Pharmaceuticals' TIGER Biosensor System Characterizes Epidemic in Military Training Camp Posted 8:36 AM PST |
| |
| Tuesday, May 24, 2005 |
| Isis Pharmaceuticals Announces Collaboration With Pfizer to Discover Antisense Drugs for the Treatment of Eye Disease Posted 8:39 AM PST |
| |
| Wednesday, May 18, 2005 |
| Isis Pharmaceuticals and Collaborators Demonstrate Anti-Cancer Effects of STAT-3 Inhibitor, According to Study in Nature Medicine Posted 8:20 AM PST |
| |
| Thursday, May 5, 2005 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for the First Quarter 2005 Posted 9:14 AM PST |
| |
| Friday, April 29, 2005 |
| Kinovate Life Sciences, Inc. Launches NittoPhase(TM) High Performance Solid Support for Oligonucleotide Synthesis Posted 9:12 AM PST |
| |
| Wednesday, April 27, 2005 |
| Isis Pharmaceuticals Enters First Asthma Drug Into Development Posted 10:28 AM PST |
| |
| Isis Pharmaceuticals to Present at the Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference Posted 4:55 PM PST |
| |
| Thursday, April 21, 2005 |
| Multiple Second-Generation Antisense Drugs Effectively Inhibit Tumor Growth and Show Potential as New Anti-Cancer Drugs Posted 5:13 PM PST |
| |
| Monday, April 18, 2005 |
| CARLSBAD, CA--- Isis Pharmaceuticals' TIGER Program Awarded $1.5 Million From The Department of Homeland Security for Microbial Forensics Posted 9:22 AM PST |
| |
| Thursday, April 14, 2005 |
| Isis Pharmaceuticals and Collaborators to Present Data From Preclinical and Clinical Studies at American Diabetes Association Annual Meeting Posted 7:55 AM PST |
| |
| Monday, April 11, 2005 |
| SciTegic Launches New Sequence Analysis Collection Posted 7:01 AM PST |
| |
| Wednesday, March 16, 2005 |
| OncoGenex Technologies and Isis Pharmaceuticals Expand Antisense Drug Development Partnershp in Oncology Posted 9:32 AM PST |
| |
| Tuesday, March 15, 2005 |
| Isis Pharmaceuticals Initiates Phase 1 Clinical Trial of Oral ISIS 301012 for Cardiovascular Disease Posted 4:58 PM PST |
| |
| Thursday, March 3, 2005 |
| MENLO PARK--- Xtent Announces $25 Million C Round Financing Posted 10:00 AM PST |
| |
| Tuesday, March 1, 2005 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for 2004; Company Previews 2005 Plans Posted 9:11 AM PST |
| |
| Friday, February 25, 2005 |
| IRVINE--- Spectrum Pharmaceuticals Strengthens Management Team and Adds Industry Expertise and Capabilities With Key Promotions and Appointments Posted 9:18 AM PST |
| |
| Monday, February 14, 2005 |
| Isis Pharmaceuticals Licenses Antisense Anti-Cancer Drug to Sarissa Posted 10:13 AM PST |
| |
| Tuesday, February 8, 2005 |
| SAN DIEGO--- Nereus Pharmaceuticals Appoints F. Andrew Dorr, MD, as Chief Medical Officer Posted 10:25 AM PST |
| |
| Monday, January 10, 2005 |
| Isis Pharmaceuticals Provides Guidance On New Corporate Structure and Research and Development Programs For 2005 Posted 9:14 AM PST |
| |
| Tuesday, January 4, 2005 |
| CARLSBAD--- Isis Pharmaceuticals Appoints Michael Treble as Chief Executive Officer of Its Ibis Program Posted 10:05 AM PST |
| |
| Tuesday, December 21, 2004 |
| Antisense Therapeutics Limited and Isis Pharmaceuticals Initiate Phase 2a Trial of Antisense Drug for Multiple Sclerosis Posted 9:32 AM PST |
| |
| SAN DIEGO--- Ichor Medical Systems Expands Management Team: David Slack Joins as Vice President, Finance and Corporate Development Posted 5:23 PM PST |
| |
| Isis Pharmaceuticals to Receive $24 Million for a Portion of Its Macugen(R) Royalty Rights Posted 5:21 PM PST |
| |
| Monday, December 20, 2004 |
| Isis Pharmaceuticals Earns $3 Million Milestone Payment from Eyetech for FDA Marketing Clearance of Macugen(TM) Posted 9:21 AM PST |
| |
| Thursday, December 16, 2004 |
| CARLSBAD--- Richard D. DiMarchi, Ph.D., Joins Isis Pharmaceuticals' Board of Directors Posted 4:42 PM PST |
| |
| Wednesday, August 11, 2004 |
| Second-Generation Antisense Drug for Cardiovascular Disease Demonstrates Significant and Durable Reductions in Cholesterol Posted 4:48 PM PST |
| |
| Thursday, August 5, 2004 |
| Isis Pharmaceuticals Reports Second Quarter 2004 Financial Results and Highlights Posted 8:57 AM PST |
| |
| Monday, July 26, 2004 |
| Isis Pharmaceuticals, Inc. Presentation at Informed Investors Security and Defense Virtual Stocks Forum to be Webcast on Thursday, July 29th Posted 9:02 AM PST |
| |
| Thursday, June 24, 2004 |
| Isis Pharmaceuticals Earns $1 Million Milestone Payment From Eyetech Related to Filing of Macugen(TM) New Drug Application Posted 9:42 AM PST |
| |
| Wednesday, June 9, 2004 |
| Second-Generation Antisense Inhibitors Provide New Insights Into Metabolic Disease and Potential Treatments Posted 6:36 PM PST |
| |
| Isis Gains Full Ownership of Orasense(TM) and HepaSense(TM) Subsidiaries and Eliminates Future Royalty Payments to Elan Posted 7:59 AM PST |
| |
| Tuesday, June 8, 2004 |
| Antisense Therapeutics Limited and Isis Pharmaceuticals Announce Positive Results From A Phase 1 Trial Of ATL-1102 for Multiple Sclerosis Posted 8:37 AM PST |
| |
| Thursday, May 6, 2004 |
| Isis Pharmaceuticals Announces Extension of Antisense Cancer Drug Discovery Collaboration With Lilly Posted 9:04 AM PST |
| |
| Isis Pharmaceuticals Reports Financial Results and Highlights for the First Quarter 2004 Posted 9:02 AM PST |
| |
| Thursday, April 29, 2004 |
| Isis Pharmaceuticals Announces 2004 First Quarter Financial Results Posted 7:08 PM PST |
| |
| Tuesday, April 27, 2004 |
| Antisense Drug Demonstrates Potential to Treat Progressive Form of ALS Posted 4:12 PM PST |
| |
| Wednesday, March 17, 2004 |
| SAN DIEGO--- Arena Pharmaceuticals Announces Management Changes Posted 8:40 AM PST |
| |
| Thursday, March 11, 2004 |
| Isis Pharmaceuticals Forms Strategic Alliance With Alnylam Pharmaceuticals in RNAi Therapeutics Posted 5:48 PM PST |
| |
| RoboDesign International, Inc. to Design and Manufacture Fully Automated Biosensor Systems for the Identification of Infectious Organisms for Isis Pharmaceuticals Posted 10:13 AM PST |
| |
| Tuesday, March 2, 2004 |
| Isis Pharmaceuticals' Ibis Program Awarded Government Contract for Up to $19.5 Million for Continued Development of TIGER Biosensor for Biological Warfare Defense Posted 5:12 PM PST |
| |
| Wednesday, February 25, 2004 |
| SAN DIEGO--- MediciNova, Inc. Acquires Phase II Premature Labor Compound from Kissei Pharmaceutical Co., Ltd.; Vice President, Regulatory Affairs Appointed to Strengthen Management Team Posted 5:27 PM PST |
| |
| Tuesday, February 10, 2004 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for 2003 Posted 9:16 AM PST |
| |
| Tuesday, January 20, 2004 |
| SAN DIEGO--- Idun Appoints Jennifer Giottonini Vice President, Corporate Development Posted 4:36 PM PST |
| |
| Wednesday, January 14, 2004 |
| Isis Pharmaceuticals Identifies SARS Antisense Drug Candidates Through Collaboration with ITRI of Taiwan Posted 8:02 AM PST |
| |
| Monday, January 5, 2004 |
| Isis Pharmaceuticals Reports Positive Data from Phase 2 Trial Of ISIS 104838 in Rheumatoid Arthritis Posted 8:29 AM PST |
| |
| Monday, December 29, 2003 |
| Isis Pharmaceuticals Initiates Phase I Study of Second-Generation Antisense Drug for Cardiovascular Disease Posted 8:50 AM PST |
| |
| Wednesday, December 17, 2003 |
| Isis Pharmaceuticals Retires $32 Million in Convertible Partner Debt With Low-Interest Five-Year Loan Posted 9:26 AM PST |
| |
| Thursday, November 20, 2003 |
| Antisense Drug Targeting Survivin Inhibits Growth Of Tumors In Animal Models; Data Support Clinical Development Posted 3:24 PM PST |
| |
| Tuesday, November 4, 2003 |
| Isis Pharmaceuticals Reports Third Quarter 2003 Highlights And Financial Results Posted 8:37 AM PST |
| |
| Monday, November 3, 2003 |
| Isis Pharmaceuticals Broadens Micro-RNA Drug Discovery Program With Support From Singapore Economic Development Board Posted 3:10 PM PST |
| |
| Monday, October 27, 2003 |
| Isis Pharmaceuticals Updates Positive Clinical Data on Multiple Antisense Drugs Posted 9:24 AM PST |
| |
| Tuesday, October 7, 2003 |
| Isis Pharmaceuticals' Ibis Program Receives $6 Million Grant from the CDC for Infectious Disease Surveillance Posted 7:49 AM PST |
| |
| Wednesday, September 17, 2003 |
| Second-Generation Type 2 Diabetes Antisense Drug Improves Glucose Tolerance Tests in Normal Volunteers in Phase 1 Study; Isis Pharmaceuticals Initiates Phase 2 Program In Patients With Type 2 Diabetes Posted 8:00 AM PST |
| |
| Thursday, May 29, 2003 |
| Isis Pharmaceuticals Initiates Phase II Clinical Trial of ISIS 14803 in Patients with Hepatitis C Posted 5:48 AM PST |
| |
| Monday, May 19, 2003 |
| Isis Pharmaceuticals and Ercole Biotech Initiate Collaboration to Create Antisense Drugs Which Control Alternative Splicing Posted 7:41 AM PST |
| |
| Wednesday, May 14, 2003 |
| Isis Pharmaceuticals Initiates Phase I Clinical Trial of Second-Generation Antisense Drug ISIS 113715 for Type 2 Diabetes Posted 7:13 AM PST |
| |
| Thursday, May 8, 2003 |
| Isis Pharmaceuticals Reports Financial Results And Highlights for the First Quarter 2003 Posted 7:55 AM PST |
| |
| Monday, May 5, 2003 |
| SAN DIEGO--- Salmedix Appoints F. Andrew Dorr, M.D. as Chief Operating Officer Posted 5:29 PM PST |
| |
| Tuesday, April 29, 2003 |
| SEQUENOM Reports First Quarter 2003 Financial Results Posted 5:54 PM PST |
| |
| Monday, April 21, 2003 |
| Isis Pharmaceuticals Achieves Milestone in Antisense Drug Discovery Collaboration With Eli Lilly and Company Posted 8:01 AM PST |
| |
| Tuesday, April 8, 2003 |
| Isis Pharmaceuticals Initiates Additional Phase II Clinical Trial Of Alicaforsen, ISIS 2302, In Patients With Ulcerative Colitis Posted 7:54 AM PST |
| |
| Wednesday, April 2, 2003 |
| Isis Pharmaceuticals Updates Operating Plan For 2003 Posted 7:41 AM PST |
| |
| SEQUENOM and Isis Pharmaceuticals Collaborate to Discover Genetic Variation in Antisense Drug Target Regions Posted 7:40 AM PST |
| |
| Thursday, March 20, 2003 |
| Hemispherx Biopharma to Present at the Strategic Research Institutes First 'SiRNA' Conference Posted 9:34 AM PST |
| |
| Wednesday, March 19, 2003 |
| Isis Pharmaceuticals Announces Live Webcast to Provide General Corporate Update Posted 9:40 AM PST |
| |
| Monday, March 17, 2003 |
| Isis Pharmaceuticals and Eli Lilly and Company Announce Results of Affinitak(TM) Phase III Clinical Trial in Non-Small Cell Lung Cancer Posted 4:42 AM PST |
| |
| Tuesday, February 11, 2003 |
| Isis Pharmaceuticals Reports Financial Results and Highlights for the Year 2002 Posted 8:25 AM PST |
| |
| Monday, February 10, 2003 |
| Isis Pharmaceuticals Earns Second Milestone in Amgen Antisense Drug Discovery Collaboration Posted 8:18 AM PST |
| |
| Thursday, January 16, 2003 |
| Isis Pharmaceuticals and atugen AG Enter Patent License Agreement Posted 7:51 AM PST |
| |
